Filing Flows › NextPlat (NXPL) › Q2 2026 › vs Q2 2025
NextPlat (NXPL) Q2 2026 vs Q2 2025 (year over year)
NextPlat's revenue fell $1.4M (-10%) from $13.2M in Q2 2025 to $11.9M in Q2 2026. The biggest changes: Pharmacy Prescription and Other Revenue, Net of PBM Fees −$2.6M (-32%); Pharmacy Contract Revenue +$1.3M (+136%).
NextPlat, Q2 2026: revenue $11.9M (-10% year over year), operating margin -1.1%, net loss $144K, operating cash flow $1.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Pharmacy Prescription and Other Revenue, Net of PBM Fees | $5.6M | $8.2M | −$2.6M | -32% |
| Pharmacy Contract Revenue | $2.2M | $947K | $1.3M | +136% |
| Revenue | $11.9M | $13.2M | −$1.4M | -10% |
| Net loss | $144K | $1.8M | −$1.6M | -92% |
| Costs & expenses | $12.1M | $15.1M | −$3.0M | -20% |
| Operating costs | $12.0M | $15.1M | −$3.1M | -20% |
| Income tax | $48K | $31K | $17K | +55% |
| Cost of revenue | $7.2M | $10.4M | −$3.2M | -31% |
| SG&A | $2.4M | $2.0M | $469K | +24% |
| Other operating costs | $2.4M | $2.7M | −$360K | -13% |
| Operating cash sources | $1.2M | $748K | $481K | +64% |
| Depreciation & amortization | $80K | $175K | −$95K | -54% |
| Working capital & other | $1.1M | $573K | $576K | +101% |
| Net loss absorbed | $144K | $1.8M | −$1.6M | -92% |
| Operating cash flow | $1.1M | −$1.0M | $2.1M | — |
Questions
How much did NextPlat's revenue grow year over year in Q2 2026?
NextPlat's revenue fell $1.4M (-10%) from $13.2M in Q2 2025 to $11.9M in Q2 2026.
What drove NextPlat's revenue change in Q2 2026?
Pharmacy Prescription and Other Revenue, Net of PBM Fees −$2.6M (-32%); Pharmacy Contract Revenue +$1.3M (+136%).